Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | STAT3 | P40763 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30362156 | 1.00 | MAPT (0.55) | MAPTALDH1A1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL343399 | 0.85 | MAPT (0.44) | MAPTALDH1A1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL1221627 | 0.85 | POLB (0.63) | MAPTALDH1A1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL30362007 | 0.85 | POLB (0.63) | MAPTALDH1A1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL3382142 | 0.84 | CFD (0.54) | MAPTALDH1A1SMN1; SMN2CYP1A2CYP2C9 | |
| Hydrochloric Acid SCHEMBL27134662 | 0.83 | POLB (0.61) | MAPTALDH1A1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL1821903 | 0.83 | PTGDR2 (0.63) | MAPTALDH1A1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL9736415 | 0.82 | KDM4E (0.53) | MAPTALDH1A1SMN1; SMN2HSD17B10POLB | |
| SCHEMBL392403 | 0.81 | ALDH1A1 (0.59) | MAPTALDH1A1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL30361998 | 0.81 | ALDH1A1 (0.59) | MAPTALDH1A1SMN1; SMN2CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221966-A1 | RXFP1 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-07-10 | — | — | US | disclosed |
| CN-118843613-A | RXFP1 agonists | 百时美施贵宝公司 | 2024-10-25 | — | — | CN | disclosed |
| US-20240174605-A1 | ARYLSULFONAMIDES AS OREXIN RECEPTOR AGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2024-05-30 | — | — | US | disclosed |
| EP-4301728-A1 | ARYLSULFOXAMIDES AS OREXIN RECEPTOR AGONISTS | Research Triangle Institute (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-117015526-A | Aryl sulfonamides as orexin receptor agonists | 研究三角协会 | 2023-11-07 | — | — | CN | disclosed |
| WO-2023076626-A1 | RXFP1 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076626-A1 | RXFP1 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2022187231-A1 | ARYLSULFOXAMIDES AS OREXIN RECEPTOR AGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2022-09-09 | — | — | WO | disclosed |
| US-9193713-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2015-11-24 | — | — | US | disclosed |
| EP-2851366-A1 | Compounds as cannabinoid receptor ligands | Abbvie Inc. (US) | 2015-03-25 | — | — | EP | disclosed |
| US-20080058335-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC. | 2008-03-06 | — | — | US | disclosed |
| WO-2007140385-A2 | THIAZOLE COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007125331-A2 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| EP-1100484-A1 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000003704-A1 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-01-27 | — | — | WO | disclosed |
| EP-0124476-B1 | CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | CIBA-GEIGY AG (CH) | 1988-06-22 | — | — | EP | disclosed |
| US-4559349-A | TREATMENT OF PHYCHOSIS | CIBA GEIGY CORPORATION (US) | 1985-12-17 | — | — | US | disclosed |
| EP-0124476-A1 | Carboxamides, process for their preparation and pharmaceutical preparations containing them | CIBA-GEIGY AG (CH) | 1984-11-07 | — | — | EP | disclosed |
| US-4278680-A | Hypoglycaemically and hypolipidaemically active derivatives of phenylacetic acid | BOEHRINGER MANNHEIM GMBH (DE) | 1981-07-14 | — | — | US | disclosed |
| US-4207341-A | Hypoglycaemically and hypolipidaemically active derivatives of phenylacetic acid | BOEHRINGER-MANNHEIM GMBH (DE) | 1980-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250221966-A1 | RXFP1 AGONISTS | RXFP1, RXFP2, RXFP3 | MAPT 4739/4885ALDH1A1 1820/4885SMN1; SMN2 4221/4885 |
| US-20240174605-A1 | ARYLSULFONAMIDES AS OREXIN RECEPTOR AGONISTS | HCRTR2, HCRTR1, NPY1R | MAPT 2141/4885ALDH1A1 2734/4885SMN1; SMN2 778/4885 |
| US-20080058335-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | MAPT 2717/4885ALDH1A1 914/4885SMN1; SMN2 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.